Takeda's Vedolizumab Approved for Inflammatory Bowel Disease in the UK

Article

Takeda plans to target gastrointestinal and oncology medications in the near future.

Takeda plans to target gastrointestinal and oncology medications in the near future.

The National Institute for Health and Care Excellence (NICE) has approved Takeda's vedolizumab (Entyvio) for the treatment of inflammatory bowel diseases (IBD) in the United Kingdom.

The cost watchdog previously rejected vedolizumab back in December, saying that it did not have enough results to prove a good treatment, or be of good value for UK patients.

Takeda came back with new data, showing vedolizumab worth as more effective than traditional therapy. It was approved to treat severely active ulcerative colitis, in March, as a good alternative to therapies like corticosteroids, which can have severe side effects. Ulcerative colitis is one aspect of IBD, the other being Crohn's disease.

Vedolizumab is now approved to treat Crohn's disease for those who do not respond to therapy with TNF-alpha inhibitors.

"After considering further information, NICE is happy to be able to recommend vedolizumab as a treatment option for those with Crohn's disease. We hope the recommendation will benefit tens of thousands of people who live with this debilitating condition," said Carole Longson, Director of NICE Centre for Health Technology Evaluation, as quoted by PharmaTimes.

Takeda has had a few mishaps this past year, including decreased sales and losing the patent for one of its top sellers, the diabetes drug, Actos.

Although Entyvio projected peak sales of $1 billion by 2020, Takeda also faces competition. Entyvio will compete against well-established medications for Crohn's, like AbbVie's Humira, Amgen's Enbel, and Johnson & Johnson's Remicade and Simponi.

Takeda's CEO, Christophe Weber, said in a statement that Takeda will focus more of its attention on gastrointestinal and oncology medications in the near future. It recently found very positive results for ixazomib, a potential successor to its drug, Velcade.

Related Videos
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
pharmacy | Image Credit: Diego Cervo - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.